ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10964	Companies
240023	Keywords
168772	Articles
129130	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 05/28/2026 at 21:04, 3 months 13 days ago

OSE Immunotherapeutics met en place un financement relais flexible en fonds propres
OSE Immunotherapeutics lance un financement relais flexible en fonds propres avec IRIS Capital Investment pour un montant pouvant atteindre 19,3 millions d'euros sur 24 mois, prolongeant ainsi son horizon de trésorerie jusqu'à fin décembre 2026

Financement Fonds Propres OSE Immunotherapeutics Horizon De Trésorerie IRIS Capital Investment
PRESS RELEASE

published on 05/28/2026 at 21:04, 3 months 13 days ago

OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
OSE Immunotherapeutics announces a flexible bridge equity financing with IRIS Capital Investment to raise €19.3 million, extending cash runway to December 2026 as part of a global financing strategy

OSE Immunotherapeutics Cash Runway Extension Bridge Equity Financing IRIS Capital Investment Global Financing Strategy
BRIEF

published on 05/22/2026 at 07:35, 3 months 20 days ago

OSE Immunotherapeutics Announces Positive Results in Ovarian Cancer Trial

Ovarian Cancer Clinical Trial Results OSE Immunotherapeutics Tedopi® TEDOVA Phase 2
BRIEF

published on 05/22/2026 at 07:35, 3 months 20 days ago

OSE Immunotherapeutics annonce des résultats positifs dans un essai clinique sur le cancer de l'ovaire

Résultats Des Essais Cliniques Tedopi® Immunothérapies OSE Cancer De L'ovaire Phase 2 De TEDOVA
PRESS RELEASE

published on 05/22/2026 at 07:30, 3 months 20 days ago

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics announces positive topline results from TEDOVA Phase 2 trial with Tedopi® in recurrent ovarian cancer, presenting at ASCO 2026. Combination with pembrolizumab improves progression-free survival

OSE Immunotherapeutics Tedopi TEDOVA Phase 2 ASCO 2026 Recurrent Ovarian Cancer
BRIEF

published on 04/30/2026 at 07:35, 4 months 11 days ago

OSE Immunotherapeutics: 2025 Financial Review and 2026 Outlook

Strategic Partnerships OSE Immunotherapeutics 2025 Financial Results Tedopi® Cash Flow 2026
BRIEF

published on 04/30/2026 at 07:35, 4 months 11 days ago

OSE Immunotherapeutics dévoile ses résultats financiers pour 2025 et sa trésorerie pour 2026.

Résultats Financiers Perte D'exploitation Feuille De Route Stratégique Position De Trésorerie Immunothérapies OSE
BRIEF

published on 04/30/2026 at 07:35, 4 months 11 days ago

OSE Immunotherapeutics : Bilan financier de 2025 et perspectives 2026

Partenariats Stratégiques OSE Immunotherapeutics Résultats Financiers 2025 Tedopi® Trésorerie 2026
BRIEF

published on 04/30/2026 at 07:35, 4 months 11 days ago

OSE Immunotherapeutics Reveals 2025 Financial Results and 2026 Cash Position

Financial Results Cash Position Strategic Roadmap Operating Loss OSE Immunotherapeutics
PRESS RELEASE

published on 04/30/2026 at 07:30, 4 months 11 days ago

OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l’exercice 2025 et sa situation de trésorerie du 1er trimestre 2026
OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l'exercice 2025 et sa situation de trésorerie du 1er trimestre 2026, montrant une trésorerie de 22,7 millions d'euros en 2025 et 17,0 millions d'euros en mars 2026, prévoyant un horizon de trésorerie stable jusqu'au 4ème trimestre 2026

Résultats Financiers Trésorerie Exercice 2025 OSE Immunotherapeutics Horizon

Accesswire

Published on 09/11/2026 at 04:00, 7 hours 13 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 12 hours 48 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 17 hours 27 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 19 hours 53 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 13 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 10:15, 58 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 1 hour 53 minutes ago

Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 2 hours 8 minutes ago

ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 2 hours 13 minutes ago

Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 09:00, 2 hours 13 minutes ago

Picton Property Income Limited - Removal

Les Echos

Published on 09/11/2026 at 07:00, 4 hours 13 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 13 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 4 hours 13 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 13 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 15 hours 43 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE